Introduction to the main indications of Serputinib/Serpatinib (Ruitu)

Selpercatinib is a highly selective RET receptor tyrosine kinase inhibitor. The core concept of its development is to precisely block the RET signaling pathway, a key oncogenic driver. RET abnormalities are uncommon in various solid tumors, but once they occur, they often play a leading role in tumor development and progression. Because of this, the indication layout of Seputinib shows typical "gene-driven" characteristics and is not limited to a single cancer type, which is representative in the tumor treatment system.

InRET fusion-positive non-small cell lung cancer (NSCLC fielddomain, seputinib is mainly used to treat adult patients with locally advanced or metastatic disease, provided that the presence of RE is confirmed by FDA-approved detection methods T gene fusion. For these patients, traditional chemotherapy or immunotherapy has limited specificity. However, by precisely inhibiting the activity of RET kinase, cepotinib can more directly intervene in tumor growth signals, so it is gradually regarded as one of the important targeted treatment options by the guidelines. Its clinical application emphasizes "detection first, then medication", which reflects the actual implementation of precision medicine in the treatment of lung cancer.

In medullary thyroid cancer, RET mutations occur almost throughout the entire course of the disease. Seputinib is indicated for patients 12 years of age and older with RET-mutated advanced or metastatic medullary thyroid cancer who require systemic therapy. The establishment of this indication has enabled some patients with limited treatment options in the past to obtain more targeted drug plans, and has further expanded the treatment possibilities for children and adolescent patients.

For RET fusion-positive thyroid cancer patients, especially those refractory to radioactive iodine, seputinib also has clear indications. The drug is suitable for patients aged 12 and above who require systemic treatment. Its treatment idea is not to replace radioactive iodine, but to provide a new targeted intervention approach after traditional treatment methods fail. In addition, seputinib is approved for use in adult patients with other RET fusion-positive solid tumors when the disease has progressed on prior systemic therapy or satisfactory alternatives are lacking.

Reference:https://en.wikipedia.org/wiki/Selpercatinib